Fig. 6.

RRM2 overexpression contributes to enzalutamide (ENZ) resistance and an immunosuppressive TIME. (A) Unsupervised hierarchical clustering of single‐cell RNA‐seq data from 77 CTCs from 13 patients with CRPC treated with enzalutamide (from GSE67980) based on expression of 21 genes from the RRM2 signature. Genes with expression that was significantly upregulated in the ENZ‐resistant CTCs of Group II are shown in red (11‐gene panel). *P < 0.05, **P < 0.01, ***P < 0.001. (B) Profiling of immune cells by CIBERSORT in the TCGA, (C) Taylor, and (D) SU2C/PCF cohorts. Significance was determined using Wilcoxon's rank‐sum test with Benjamini–Hochberg correction.